Foreign media: The CEO of Swiss pharmaceutical giant Roche, Thomas Schinecker, said that the agreement between the US and pharmaceutical companies to lower drug prices may lead to higher prices for new drugs in Switzerland in the future.
According to the agreement, Roche's US subsidiary Genentech will cut the prices of medicines sold to the US Medicaid program. Schinecker said that the US hopes other wealthy countries invest more in innovation, and if a country's per capita GDP is higher than that of the US, the price of medicines will be correspondingly increased. Switzerland has a higher per capita GDP than the US, so the price of new drugs may increase in the future. If Switzerland resists the price increase, the introduction of new drugs may be delayed.
Roche is negotiating with multiple countries, including Germany and Japan, on drug pricing, and it is expected that pricing issues will affect Switzerland's negotiations with the US on reducing tariffs on Swiss goods.
Original article: toutiao.com/article/1852088745839616/
Statement: This article represents the views of the author alone.